A Phase II Safety and Efficacy Study on Prognosis of Moderate Pneumonia in COVID-19 patients with Regular Intravenous Immunoglobulin Therapy

BACKGROUND: Currently, there is no specific drug for the treatment of COVID-19. Therapeutic benefits of intravenous immunoglobin (IVIG) have been demonstrated in wide range of diseases. The present study is conducted to evaluate the safety and efficacy of IVIG in the treatment of COVID-19 patients w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Infect Dis
Main Authors: R S, Raman, Barge, Vijaykumar Bhagwan, Darivenula, Anil Kumar, Dandu, Himanshu, Kartha, Rakesh R, Bafna, Varun, Aravinda, Vishaly T, Raghuram, Thummala C
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2021
Assuntos:
Major Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7928808/
https://ncbi.nlm.nih.gov/pubmed/33585890
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiab098
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados